FDA Grants Fast Track Designation to RPTR-1.201 for Advanced TNBC

The FDA has granted fast track designation to RPTR-1.201, an investigational T-cell receptor (TCR) bispecific immune medicine, for the treatment of patients with advanced triple-negative breast cancer (TNBC).¹ This regulatory milestone aims to expedite the development and review of the therapy for a patient population with high unmet clinical needs.

The designation is supported by the ongoing phase 1/2 clinical trial (NCT07293754), which is evaluating the safety, tolerability, and preliminary efficacy of RPTR-1.201 as both a monotherapy and in combination with anti–PD-1 therapy in patients with advanced solid tumors, including those with TNBC.² The fast track program allows for more frequent communication with the FDA and provides the potential for rolling review of a biologics license application (BLA).¹

Clinical Rationale and Mechanism of Action

TNBC remains one of the most challenging subtypes of breast cancer to treat due to the lack of estrogen receptor, progesterone receptor, and HER2 expression. While immune checkpoint inhibitors have improved outcomes for some patients with PD-L1–positive disease, those who progress after standard-of-care chemotherapy and immunotherapy face limited options and poor overall survival.

RPTR-1.201 is a soluble TCR bispecific molecule engineered to bridge the gap between the patient’s own T cells and tumor cells. The therapeutic utilizes a high-affinity, engineered TCR domain that recognizes a tumor-selective epitope presented by the HLA-A*02:01 molecule on the surface of malignant cells. This TCR domain is fused to an anti-CD3 moiety, which facilitates the recruitment and activation of polyclonal T cells at the tumor site, bypassing the need for endogenous TCR recognition of the tumor.

"Patients with advanced TNBC often face limited options after progression on standard therapies," said Robert Andtbacka, MD, CM, chief medical officer of Repertoire Immune Medicines, in a news release. "Fast [tr]ack [d]esignation underscores the seriousness of this disease and the unmet needs for new treatment options. RPTR-1-201 is designed to redirect T cells by targeting a tumor-selective epitope on tumor cells in selected patients, and we appreciate the FDA's engagement as we evaluate its potential in this population."

The molecule was discovered using the proprietary DECODE platform, which employs artificial intelligence and high-throughput immune synapse mapping to identify rare, tumor-specific TCR-epitope pairs. Unlike traditional adoptive cell therapies, which require complex ex vivo cell manipulation, RPTR-1.201 is an "off-the-shelf" biologic designed to redirect the existing immune repertoire against specific tumor antigens.

Ongoing Clinical Evaluation (RaPTR-101)

The clinical development of RPTR-1.201 is centered on the RaPTR-101 trial, a multicenter, open-label phase 1/2 study.² The trial is divided into dose-escalation and dose-expansion phases. The expansion cohorts are specifically designed to evaluate the clinical activity of RPTR-1.201 in specific histological settings, including metastatic TNBC and other solid tumors where the target epitope is prevalent.

The primary end points for the phase 1 portion of the trial include the incidence of dose-limiting toxicities and the determination of the recommended phase 2 dose. Secondary end points focus on objective response rates per RECIST v1.1, duration of response, and progression-free survival.

Future Directions in TCR Therapeutics

The development of TCR bispecifics like RPTR-1.201 represents a growing frontier in precision oncology. By targeting intracellular antigens, which comprise approximately 90% of all tumor-specific proteins, TCR-based therapies can access a broader array of targets than traditional CAR T therapies or monoclonal antibodies, which are limited to surface-expressed proteins.

As the RaPTR-101 trial progresses, investigators will also monitor for potential immune-related adverse events, such as cytokine release syndrome (CRS), which are characteristic of T-cell-engaging therapies. Early clinical data from the trial are expected to guide further late-stage development and potential registrational pathways.

REFERENCES

1. Repertoire Immune Medicines Announces FDA Fast Track Designation for its Investigational Immune Medicine, RPTR-1-201. News release. Repetoire Immune Medicines. May 7, 2026. Accessed May 8, 2026. https://tinyurl.com/yc243utw

2. An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors (RaPTR-101). ClinicalTrials.gov. Updated February 17, 2026. Accessed May 8, 2026. https://clinicaltrials.gov/study/NCT07293754